1. Show article details.

    BRIEF-Bioventus To Expand Operations And Manufacturing In Memphis

    Reuters – 8:47 AM ET 11/18/2021

    Bioventus Inc (BVS): * BIOVENTUS TO EXPAND OPERATIONS AND MANUFACTURING IN MEMPHIS. * Bioventus Inc (BVS) - EXPECTS TO MOVE ITS 116 EMPLOYEES INTO NEW SPACE IN EARLY Q3 OF 2022 AND ADD ANOTHER 40 JOBS IN NEXT FIVE YEARS Source text for Eikon: Further company coverage:

  2. Show article details.

    Bioventus to Expand Operations and Manufacturing in Memphis

    GlobeNewswire – 8:45 AM ET 11/18/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, has signed a lease agreement to double its current operations and manufacturing space and relocate from its current facility in suburban Memphis.

  3. Show article details.

    BRIEF-Bioventus Announces Chief Financial Officer Transition Plan

    Reuters – 7:41 AM ET 11/15/2021

    Bioventus Inc (BVS): * BIOVENTUS ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION PLAN. * Bioventus Inc (BVS) - GREG ANGLUM IS TRANSITIONING FROM HIS ROLE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER TO PURSUE OTHER CAREER OPPORTUNITIES. * Bioventus Inc (BVS) - ANGLUM WILL REMAIN IN HIS CURRENT ROLE UNTIL A SUCCESSOR IS NAMED Source text for Eikon: Further company coverage:

  4. Show article details.

    Bioventus Announces Chief Financial Officer Transition Plan

    GlobeNewswire – 7:30 AM ET 11/15/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, today announced that Greg Anglum is transitioning from his role as Senior Vice President and Chief Financial Officer to pursue other career opportunities. “I want to thank Greg for his dedication to Bioventus (BVS) over the past five years,” commented Ken Reali, Bioventus’ Chief Executive Officer.

  5. Show article details.

    BRIEF-Bioventus Reports Third Quarter Results Updates Full-Year 2021 Financial Guidance

    Reuters – 7:40 AM ET 11/09/2021

    Bioventus Inc (BVS): * BIOVENTUS REPORTS THIRD QUARTER RESULTS; UPDATES FULL-YEAR 2021 FINANCIAL GUIDANCE. * Q3 SALES ROSE 26.8 PERCENT TO $108.9 MILLION. * SEES FULL-YEAR 2021 NET SALES OF $425 MILLION-$430 MILLION. * QTRLY LOSS PER SHARE $0.03. * QTRLY NON-GAAP EARNINGS PER SHARE $0.25 Source text for Eikon: Further company coverage:

  6. Show article details.

    Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance

    GlobeNewswire – 7:00 AM ET 11/09/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, today reported financial results for three and nine months ended October 2, 2021.

  7. Show article details.

    Sharon Klugewicz Joins Bioventus as Senior Vice President, Quality and Regulatory Affairs

    GlobeNewswire – 8:30 AM ET 11/01/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, has appointed Sharon Klugewicz as Senior Vice President, Quality and Regulatory Affairs. “We are very pleased to welcome Sharon to Bioventus (BVS) as she helps us integrate Misonix into the Company and lead this important function,” said Ken Reali, CEO, Bioventus.

  8. Show article details.

    Bioventus Completes the Acquisition of Misonix

    GlobeNewswire – 8:25 AM ET 10/29/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, has completed the acquisition of Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes, for cash and common stock.

  9. Show article details.

    Bioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

    GlobeNewswire – 4:15 PM ET 10/27/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, today announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Tuesday, November 9, 2021. Management will host a conference call to discuss its financial results and provide a business update, with a question and answer session, at 8:30 a.m. Eastern Time on November 9, 2021.

  10. Show article details.

    BRIEF-Bioventus And Misonix Stockholders Approve The Acquisition Of Misonix By Bioventus

    Reuters – 7:15 PM ET 10/26/2021

    Bioventus Inc (BVS): * BIOVENTUS AND MISONIX STOCKHOLDERS APPROVE THE ACQUISITION OF MISONIX BY BIOVENTUS Source text for Eikon: Further company coverage:

  11. Show article details.

    Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus

    GlobeNewswire – 4:15 PM ET 10/26/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, and Misonix, Inc. (MSON), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that the stockholders of Bioventus (BVS) approved the issuance of shares of Bioventus (BVS) class A common stock to the stockholders of Misonix (MSON) in connection with the previously an...

  12. Show article details.

    BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of 5:00 p.m. New York City Time, on October 25, 2021 for Misonix Stockholders to Elect Form of Merger Consideration

    GlobeNewswire – 8:00 AM ET 10/18/2021

    Bioventus Inc. (BVS) and Misonix, Inc. (MSON), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 for stockholders of Misonix (MSON) to elect the form of consideration they wish to receive for their shares of Misonix (MSON) common stock in connection with the proposed merger of Oyster Merger Sub I, Inc., a newly-formed, wholly-owned subsidiary of Bioventus (BVS), with and into Misonix (MSON), i...

  13. Show article details.

    DUROLANE® Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarthritis Pain by American Academy of Orthopaedic Surgeons

    GlobeNewswire – 8:30 AM ET 09/20/2021

    Bioventus Inc. (BVS), a leader in innovations for active healing, announced that the American Academy of Orthopaedic Surgeons recently released updated clinical practice guidelines indicating that high molecular weight cross-linked hyaluronic treatments, including Bioventus (BVS) treatment DUROLANE, showed statistically significant improvement in certain knee osteoarthritis patients.

  14. Show article details.

    BRIEF-Misonix Q4 Loss Per Share $0.26

    Reuters – 4:05 PM ET 09/02/2021

    Misonix Inc (MSON): * MISONIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS. * Q4 REVENUE $19.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $19 MILLION. * Q4 LOSS PER SHARE $0.26 Source text for Eikon: Further company coverage:

  15. Show article details.

    Misonix Reports Fourth Quarter and Fiscal Year 2021 Financial Results

    GlobeNewswire – 4:01 PM ET 09/02/2021

    Misonix, Inc. (MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below:    Definitions and disclosures regarding non-GAAP financial information including reconciliations are included a...

  16. Show article details.

    Bioventus Proceeds with Option Structure Agreement with CartiHeal

    GlobeNewswire – 7:30 AM ET 08/30/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, has elected to make a $50 million escrow payment pursuant to its Option and Equity Purchase Agreement with CartiHeal Ltd., signaling its intent to move forward with an acquisition of CartiHeal.

  17. Show article details.

    Bioventus Invests in Trice Medical Minimally Invasive Technologies

    GlobeNewswire – 4:05 PM ET 08/25/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, has completed a strategic investment in Trice Medical, Inc., a company focused on developing and commercializing minimally invasive technologies for sports medicine and orthopedic surgical procedures.

  18. Show article details.

    Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer

    GlobeNewswire – 8:30 AM ET 08/23/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, has appointed Dave Crawford as its Vice President, Investor Relations and Treasurer. “We are happy to welcome Dave to lead our investor relations department and manage treasury at Bioventus,” said Greg Anglum, Senior Vice President and CFO.

  19. Show article details.

    Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance

    GlobeNewswire – 4:05 PM ET 08/10/2021

    Bioventus Inc. (BVS), a global leader in innovations for active healing, today reported financial results for three and six months ended July 3, 2021. Q2 Financial Summary & Recent Highlights: *See below under “Use of Non-GAAP Financial Measures” for a definition and reconciliation of this measure. 1 Prior guidance was provided on July 29, 2021.

  20. Show article details.

    Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix

    GlobeNewswire – 4:05 PM ET 07/29/2021

    DURHAM, N.C. and FARMINGDALE, N.Y., July 29, 2021 -- Bioventus Inc. (BVS), a global leader in innovations for active healing, and Misonix, Inc. (MSON), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus (BVS) will acquire Misonix (MSON) in a cash-and-stock tran...

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    09

    BVS announced Q3 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.